Jafron Biomedical Valuation
| 300529 Stock | 29.96 0.10 0.33% |
At this time, the firm appears to be overvalued. Jafron Biomedical retains a regular Real Value of USD25.45 per share. The prevalent price of the firm is USD29.96. Our model calculates the value of Jafron Biomedical from evaluating the firm fundamentals such as Return On Asset of 0.11, return on equity of 0.25, and Current Valuation of 22.83 B as well as inspecting its technical indicators and probability of bankruptcy.
Price Book 7.274 | Enterprise Value 22.8 B | Enterprise Value Ebitda 21.9786 | Price Sales 9.1662 | Trailing PE 30.21 |
Overvalued
Today
Please note that Jafron Biomedical's price fluctuation is not too volatile at this time. Calculation of the real value of Jafron Biomedical is based on 3 months time horizon. Increasing Jafron Biomedical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Jafron Biomedical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Jafron Stock. However, Jafron Biomedical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 29.96 | Real 25.45 | Hype 29.45 | Naive 29.27 |
The real value of Jafron Stock, also known as its intrinsic value, is the underlying worth of Jafron Biomedical Company, which is reflected in its stock price. It is based on Jafron Biomedical's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Jafron Biomedical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Jafron Biomedical Co helps investors to forecast how Jafron stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Jafron Biomedical more accurately as focusing exclusively on Jafron Biomedical's fundamentals will not take into account other important factors: Jafron Biomedical Cash |
|
Jafron Biomedical Total Value Analysis
Jafron Biomedical Co is presently forecasted to have takeover price of 22.83 B with market capitalization of 24.13 B, debt of 261.83 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Jafron Biomedical fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
22.83 B | 24.13 B | 261.83 M |
Jafron Biomedical Investor Information
About 51.0% of the company shares are owned by insiders or employees . The company last dividend was issued on the 31st of May 2024. Jafron Biomedical had 1.9:1 split on the 20th of May 2020. Based on the analysis of Jafron Biomedical's profitability, liquidity, and operating efficiency, Jafron Biomedical Co is performing exceptionally good at this time. It has a great probability to report excellent financial results in December.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 518.8 M | 916.7 M |
|
| |||||
| Operating Income | 528.6 M | 523.2 M |
|
|
Jafron Biomedical Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Jafron Biomedical has an asset utilization ratio of 34.68 percent. This suggests that the Company is making USD0.35 for each dollar of assets. An increasing asset utilization means that Jafron Biomedical Co is more efficient with each dollar of assets it utilizes for everyday operations.Jafron Biomedical Ownership Allocation
Jafron Biomedical Co has a total of 798.6 Million outstanding shares. Jafron Biomedical secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Jafron Biomedical Profitability Analysis
The company reported the revenue of 1.92 B. Net Income was 436.49 M with profit before overhead, payroll, taxes, and interest of 2.27 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Jafron Biomedical's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Jafron Biomedical and how it compares across the competition.
About Jafron Biomedical Valuation
The stock valuation mechanism determines Jafron Biomedical's current worth on a weekly basis. Our valuation model uses a comparative analysis of Jafron Biomedical. We calculate exposure to Jafron Biomedical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Jafron Biomedical's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1.5 B | 1.4 B |
Jafron Biomedical Quarterly Retained Earnings |
|
Complementary Tools for Jafron Stock analysis
When running Jafron Biomedical's price analysis, check to measure Jafron Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jafron Biomedical is operating at the current time. Most of Jafron Biomedical's value examination focuses on studying past and present price action to predict the probability of Jafron Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jafron Biomedical's price. Additionally, you may evaluate how the addition of Jafron Biomedical to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |